U.S. childhood and teen obesity rates have reached record-highs while adult obesity rates may be slowing, according to two ...

Ivim Health reports hair loss from GLP-1 medications like Ozempic is typically temporary, linked to rapid weight loss, not the drugs.

During the State of the Union on Tuesday night, President Donald Trump pointed to lower drug prices as an achievement of the ...

Judge Karen Marston of the Eastern District of Pennsylvania issued the Order on February 23, 2026 Appointing Jason Goldstein to Co-Chair of the Plaintiffs' Executive Committee and Federal-State Court ...

The Indianapolis pharma giant announced it will acquire Orna Therapeutics for $2.4 billion, putting Lily in the rat race to develop injectable, in vivo CAR-T therapies to eliminate the costly cell ...

In this video, Melissa Shoemaker, MD, MPH, discusses how the obesity treatment landscape has changed in recent years.

Since 2023, Eli Lilly and Co. has filed lawsuits against dozens of compound pharmacies, weight-loss centers and health spas that produced and sold copies of Mounjaro and Zepbound.

After finding itself some unwanted attention this week, Novo Nordisk (NYSE:NVO) has dropped 22% in the past week and 56% over ...

In this week’s edition of InnovationRx, we look at cheaper biologic drugs, Novo Nordisk’s $2 billion next-gen obesity drug deal, new ways of fighting cancer, and more.

Hims & Hers Health is facing existential risk as regulatory uncertainty and margin erosion undermine its growth narrative. Click here to read why HIMS is a Sell.

On February 24, BofA said Novo Nordisk’s decision to cut GLP-1 list prices may draw attention, but the firm does not expect a ...